Skip to content

Investors / Press Releases


The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.


Filter Releases
 
Press Releases
Date Title and Summary View
Mar 21, 2017
NEW YORK, BEDMINSTER, N.J., and DUBLIN, Ireland, March 21, 2017 (GLOBE NEWSWIRE) -- The American Heart Association and American Stroke Association announced today that John Thero will serve as chairman of its annual Heart & Stroke Ball scheduled for June 14, 2017 in New York City. The American Heart Association and American Stroke Association's ...
Mar 16, 2017
Mar 15, 2017
BEDMINSTER, N.J. and DUBLIN, Ireland, March 15, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced the publication today of the rationale and design for the company's REDUCE-IT Phase 3 cardiovascular outcomes study in Clinical Cardiology, available at: http://onlinelibrary.wiley.com/doi/10.1002/clc.22692/full. Deepak L. Bh...
Feb 28, 2017
$130.1 Million and $38.7 Million Total Revenue for Full Year and Fourth Quarter 2016 Reflect Increases of 59% and 45% Compared to Corresponding Periods in 2015  REDUCE-IT Cardiovascular Outcomes Study Remains on Schedule to Reach Onset of Final Target Event Near the End of 2017Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, ...
Feb 22, 2017
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the co...
Feb 9, 2017
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the company will participate in the Leerink Partners 6th Annual Global Healthcare Conferen...
Jan 20, 2017
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 20, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) ("Amarin") announced today that it and its wholly owned subsidiary, Corsicanto II Designated Activity Company (the "Issuer"), have entered into separate, privately negotiated purchase agreements with certain investors pursuant to which the...
Jan 5, 2017
Unaudited Full-Year 2016 Net Product Revenue Estimated to Modestly Exceed Upper End of $112 to $125 Million Previously Guided Range Anticipate Full-Year 2017 Net Product Revenues Between $155 Million and $165 Million; Commercial Operations Positioned to be Cash Flow Positive for 2017 BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 05, 2017 (GLOB...
Dec 16, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (the "Company") announced today that it is providing a contractual reminder to holders of the outstanding 3.50% Exchangeable Senior Notes due 2032 (CUSIP Number: 220480 AC1) (the "Notes") of its wholly owned subsidiary, Corsicanto Designat...
Nov 14, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced an oral presentation at the American Heart Association Scientific Sessions 2016, New Orleans on November 14, 2016 that further characterized the efficacy and safety of Vascepa® (icosapent ethyl) in statin-treated women...
Nov 11, 2016
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a ...
Nov 3, 2016
Third Quarter Net Product Revenue Up 52% vs. Prior Year Period Maintaining Guidance on 2016 Net Product Revenue at $112-$125 Million;Anticipate Upper Half of RangeManagement to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceu...
Oct 27, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the com...
Oct 25, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today the introduction of a smaller 0.5-gram capsule size for Vascepa® (icosapent ethyl) available now in retail pharmacies nationwide. The smaller capsule is in addition to the original and currently available 1-gram size V...
Sep 12, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced that, as expected, the independent data monitoring committee (DMC) has completed its review of the first pre-specified interim efficacy analysis for the REDUCE-IT cardiovascular outcomes study and has recommended that the trial ...
Sep 7, 2016
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a gener...
Aug 31, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced that randomization of patients into the REDUCE-IT cardiovascular outcomes study has been completed with 8,175 individual patients randomized, in accordance with the study protocol, on a 1:1 basis between Vascepa® (icosapent ...
Aug 26, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 26, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), announced today that its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the "Issuer"), provided notice that the Issuer has exercised its option to mandatorily exch...
Aug 15, 2016
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares ("ADSs"), the underwriters of the offering have exercised in full their option to purchase up to an aggregate of 3...
Aug 11, 2016
BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the pricing of an underwritten public offering of 21,100,000 American Depositary Shares ("ADSs") at a price to the public of $2.85 per ADS. The net proceeds to the company from this offering are expected to be approximatel...
Aug 10, 2016
BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it has commenced an underwritten public offering of its American Depositary pursuant to a shelf registration.  All of the shares in the proposed offering are to be sold by Amarin.  The offering is subject to market co...
Aug 4, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/04/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three and six months ended June 30, 2016, and provided an update on compan...
Aug 4, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/04/16 -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the U.S. Food and Drug Administration (FDA) agreed to an amendment of the company's special protocol assessment (SPA) agreement for the REDUCE-IT cardiovascular outcomes study reaffirming concurrence on critical components...
Jul 28, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 07/28/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company'...
Jul 6, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 07/06/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a gen...
Jun 30, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 06/30/16 -- Amarin Corporation plc (NASDAQ: AMRN) announced that starting today Michael W. Kalb has joined its senior management team as senior vice president and chief financial officer. A seasoned financial executive, Mr. Kalb brings over 20 years of international financial operations and acc...
Jun 11, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 06/11/16 -- Amarin Corporation plc (NASDAQ: AMRN) today announced additional data on Vascepa (icosapent ethyl) presented at the annual meeting of the American Diabetes Association (ADA) supporting its efficacy in reducing concentrations of potentially atherogenic lipoproteins (lipoproteins th...
Jun 6, 2016
BEDMINSTER, NJ AND DUBLIN, IRELAND -- (Marketwired) -- 06/06/16 --  Amarin Corporation plc (NASDAQ: AMRN) today announced that new data related to Vascepa® (icosapent ethyl) will be presented at the upcoming American Diabetes Association (ADA) 76th Scientific Sessions in New Orleans (June 10-14) and published as an abstract in the Diabe...
Jun 1, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 06/01/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a...
May 31, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 05/31/16 -- Amarin Corporation plc (NASDAQ: AMRN) announced today that the U.S. Food and Drug Administration (FDA) has determined that Vascepa® (icosapent ethyl) capsules are eligible for five-year, new chemical entity (NCE), marketing exclusivity pursuant to the Hatch-Waxman Amend...
May 20, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 05/20/16 -- Amarin Corporation plc (NASDAQ: AMRN) today announced the presentation of a poster at the annual meeting of the National Lipid Association (NLA) further characterizing the efficacy and safety of Vascepa® (icosapent ethyl) in women with very high triglyceride levels. ...
May 11, 2016
BEDMINSTER, NJ AND DUBLIN, IRELAND -- (Marketwired) -- 05/11/16 -- Amarin Corporation plc (NASDAQ: AMRN) today announced that new data related to Vascepa® (icosapent ethyl) and eicosapentaenoic acid (EPA) will be presented at the upcoming National Lipid Association 2016 Scientific Sessions in New Orleans (May 19-22). Data ...
May 5, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 05/05/16 --  Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended March 31, 2016, and provided an update on company ope...
Apr 28, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 04/28/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the c...
Apr 4, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 04/04/16 --  Amarin Corporation plc (NASDAQ: AMRN) today announced two posters presented yesterday at the annual meeting of the American College of Cardiology (ACC). This research adds to the growing body of clinical and pre-clinical data relevant to the use of EPA with statins. ...
Mar 31, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 03/31/16 -- Amarin Corporation plc (NASDAQ: AMRN) today announced that target patient enrollment has been reached in its REDUCE-IT cardiovascular outcomes trial of Vascepa (icosapent ethyl). Amarin also announced that the onset of approximately 60% of the target aggregate number of prim...
Mar 9, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 03/09/16 -- Amarin Corporation plc (NASDAQ: AMRN) announced today that the Honorable Judge Paul A. Engelmayer of the United States District Court for the Southern District of New York has approved the settlement terms proposed by the parties related to the Amarin First Amendment litigati...
Mar 8, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 03/08/16 -- Amarin Corporation plc (NASDAQ: AMRN) announced today settlement terms have been reached among the parties to resolve the Amarin First Amendment litigation (Amarin Pharma, Inc. et al. v. FDA et al., No. 15-3588 (S.D.N.Y. May 7, 2015)). Under the terms, the U.S. Food and Drug ...
Feb 25, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 02/25/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter and year ended December 31, 2015, and provided an update on...
Feb 18, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 02/18/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the c...
Feb 17, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND  -- (Marketwired) -- 02/17/16 -- Amarin Corporation plc (NASDAQ: AMRN), announced today that parties to the Amarin First Amendment litigation have jointly requested a continued stay in court proceedings. Following the August 7, 2015 preliminary relief order granted in favor of Amarin and the physician plain...
Jan 21, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 01/21/16 -- Amarin Corporation plc (NASDAQ: AMRN) has appointed Craig B. Granowitz, M.D., Ph.D. to the position of chief medical officer. In this role, Dr. Granowitz will provide strategic and operational leadership across multiple functions including medical affairs, drug safety and med...
Jan 11, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 01/11/16 -- Amarin Corporation plc (NASDAQ: AMRN), today provided a business update, including preliminary unaudited fourth quarter and full year 2015 revenue and 2016 revenue outlook. Amarin plans to discuss these results and expectations for the coming year with investors in conjunctio...
Dec 14, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 12/14/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that it has been selected for addition to the NASDAQ Biotechnology Index effective December 21, 2015...
Dec 2, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 12/02/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general...
Nov 24, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 11/24/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general...
Nov 20, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 11/20/15 -- Amarin Corporation plc (NASDAQ: AMRN) ("Amarin") announced today that it and its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the "Issuer"), have entered into separate, privately negotiated purchase agreements with c...
Nov 9, 2015
BEDMINSTER, NJ AND DUBLIN, IRELAND -- (Marketwired) -- 11/09/15 -- Amarin Corporation plc (NASDAQ: AMRN) today commented on new data from the CHERRY study that supports the hypothesis under investigation in Amarin's cardiovascular outcomes study of Vascepa® (icosapent ethyl) capsules, the REDUCE-IT trial: that highly purified EPA drug therapy...
Nov 4, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 11/04/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three and nine months ended September 30, 2015, and provided an update on c...
Oct 28, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 10/28/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's...
Sep 2, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 09/02/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general...
Aug 27, 2015
EDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/27/15 -- Amarin Corporation plc (NASDAQ: AMRN) today announced the encore presentation of findings from a post-hoc analysis examining the effects of icosapent ethyl (Vascepa®) on Apolipoprotein C-III (ApoC-III) levels in both very high triglyceride (VHTG) and high triglyceride (HTG) pati...
Aug 11, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/11/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the promotion of Joseph T. Kennedy to Executive Vice President, General Counsel and Strategic Initiat...
Aug 7, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/07/15 -- Amarin Corporation plc (NASDAQ: AMRN) today announced a United States District Court has ruled that Amarin may promote to healthcare professionals certain uses of Amarin's lead product, Vascepa®(icosapent ethyl) capsules, that are not covered by current FDA-approved labeling fo...
Aug 6, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/06/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three and six months ended June 30, 2015, and provided an update on company...
Jul 31, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 07/31/15 -- Amarin Corporation plc (NASDAQ: AMRN) today announced the presentation of findings from two studies, a retrospective study in which patients were switched from an EPA plus DHA combination product to EPA-only Vascepa® (icosapent ethyl) as well as a sub-analysis of th...
Jul 30, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 07/30/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's...
Jun 11, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 06/11/15 -- Amarin Corporation plc (NASDAQ: AMRN) announced today the presentation of findings from a new in vitro study at the National Lipid Association Scientific Sessions being held June 11-14 in Chicago. The study of the inhibitory effect of eicosapentaenoic acid (EPA) on the formation of...
Jun 8, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 06/08/15 -- Amarin Corporation plc (NASDAQ: AMRN) announced today the presentation of findings from a new in vitro study at a peer-reviewed poster session at the American Diabetes Association Scientific Sessions in Boston, Massachusetts. The poster, titled "Eicosapentaenoic Acid (EPA)...
May 28, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 05/28/15 -- Amarin Corporation plc (NASDAQ: AMRN), announced today that Judge Randolph D. Moss of the federal district court for the District of Columbia has granted Amarin's motion for summary judgment in the company's lawsuit against the United States Food and Drug Administration (FDA) seekin...
May 26, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 05/26/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general...
May 8, 2015
BEDMINSTER, NJ, and DUBLIN, IRELAND -- (Marketwired) -- 05/08/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended March 31, 2015, and provided an update on company operations...
May 5, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 05/05/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's...
Apr 8, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 04/08/15 -- Amarin Corporation, plc (NASDAQ: AMRN) and Walk with a Doc, a national nonprofit organization, today announced a 2015 partnership to expand the reach of their national health awareness efforts. Walk with a Doc is a free participation, year-round walking program held in co...
Mar 16, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 03/16/15 -- Study Shows Unique Protection of Small Dense LDL From Oxidative Damage That Results in Endothelial Cell Benefits Amarin Corporation Plc (NASDAQ: AMRN) announced today the presentation of findings from a new in vitro study s...
Mar 6, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 03/06/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it has entered into a definitive securities subscription agreement with a group of institutional...
Mar 4, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 03/04/15 -- Amarin Corporation Plc (NASDAQ: AMRN), announced today the presentation of findings from a new in vitro study that the combination of eicosapentaenoic acid (EPA), an omega-3 fatty acid, and the active metabolite of atorvastatin (ATM) provided significantly increased nitric oxide ...
Mar 3, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 03/03/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter and year ended December 31, 2014, and provided an update on company...
Mar 2, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / March 2, 2015 / Amarin Corporation plc (NASDAQ: AMRN) will host a conference call and live webcast to discuss the results of the fourth quarter and fiscal year 2014, to be held Tuesday, March 3, 2015 at 4:30 PM Eastern Time. To participate in this event, dial 877-407-8033 domestically, or...
Feb 26, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND, and MACAO S.A.R, PEOPLE'S REPUBLIC OF CHINA -- (Marketwired) -- 02/26/15 -- Amarin Corporation plc (NASDAQ: AMRN) and Eddingpharm, two pharmaceutical companies focused on the development and commercialization of innovative therapeutics, today announced an exclusive agreement for Eddingpharm to develop and commerc...
Feb 23, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 02/23/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's...
Jan 5, 2015
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 01/05/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general...
Dec 4, 2014
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 12/04/14 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general...
Nov 17, 2014
BEDMINSTER, NJ and DUBLIN, IE -- (Marketwired) -- 11/17/14 -- Amarin Corporation Plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the presentation of new data and related analyses from the MARINE and ANCHOR phase 3 studies. The data...
Nov 13, 2014
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 11/13/14 -- Making the right deal can meaningfully impact and improve your health when it comes to speaking with your doctor. Rick Harrison, star of the hit television show, "Pawn Stars®," will attend the American Heart Association's (AHA) Scientific Sessions to raise awareness of very hi...
Nov 6, 2014
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 11/06/14 --  Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three and nine months ended September 30, 2014, and provided an update on...
Nov 5, 2014
Category: Baystreet Newswire Company: Issuer Direct ID: 422545 Date: Wednesday, November 05, 2014 Ticker: NASDAQ:AMRN BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / November 5, 2014 / Amarin Corporation plc (NASDAQ:AMRN) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be...
Oct 30, 2014
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 10/30/14 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's...
Sep 16, 2014
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 09/16/14 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with...
Sep 12, 2014
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 09/12/14 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the Office of New Drugs (OND) within the U.S. Food and Drug Administration (FDA) ha...
Sep 3, 2014
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 09/03/14 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general...
Aug 7, 2014
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/07/14 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter and six months ended June 30, 2014, and provided an update on compa...
Aug 5, 2014
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/05/14 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's...
Jun 25, 2014
NEW YORK, June 25, 2014 /PRNewswire/ -- Amarin Corporation, plc (Nasdaq: AMRN), today announced a national partnership with Rick Harrison, star of the hit television show "Pawn Stars®," in launching Lower My Trigs™, a national awareness campaign about seeking treatment for very high triglycerides (VHTG) (> 500 mg/dL), a problem faced by ...
Jun 11, 2014
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 06/11/14 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the publication of a retrospective analysis of patient cases that examined the effect on lipid parame...
Jun 4, 2014
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 06/04/14 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general...
May 29, 2014
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 05/29/14 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to presen...
May 15, 2014
BEDMINSTER, N.J. and DUBLIN, Ireland, May 15, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) ("Amarin"), announced today that it and its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the "Issuer"), have entered into separate, privately negotiated exchange agreements wit...
May 9, 2014
BEDMINSTER, N.J. and DUBLIN, Ireland, May 9, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended March 31, 2014, and provided an update on company operation...
May 5, 2014
BEDMINSTER, N.J., and DUBLIN, Ireland, May 5, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the compan...
May 2, 2014
BEDMINSTER, N.J., and DUBLIN, Ireland, May 2, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the presentation at the National Lipid Association Annual Scientific Sessions, of new post-hoc ana...
Mar 31, 2014
BEDMINSTER, N.J., DUBLIN, Ireland, and MONTGOMERY, Ala., March 31, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) and Kowa Pharmaceuticals America, Inc., two biopharmaceutical companies focused on the development and commercialization of therapeutics to improve cardiovascular health, today announced an agreement to co-promote Amarin'...
Feb 27, 2014
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late stage biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter and year ended December 31, 2013, and provided an up...
Feb 24, 2014
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the compa...
Feb 21, 2014
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 21, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Food and Drug Administration (FDA) has awarded three years of marketing exclusivity...
Feb 6, 2014
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general c...
Feb 4, 2014
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that industry veteran, Aaron Berg, has been promoted to Senior Vice President, Marketing and Sale...
Jan 21, 2014
Conference Call Set for 8:00 a.m. ET today Amarin Plans Appeal to FDA Office Level, No FDA sNDA Action Expected During Appeal BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 21, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to i...
Jan 15, 2014
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 15, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the Division of Metabolism and Endocrinology Products (DMEP) within the U.S. Food and Drug ...
Dec 20, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Food and Drug Administration (FDA) notified the company last night that the FDA doe...
Dec 16, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the appointment of current President, John F. Thero, as President and Chief Executive Officer of...
Dec 2, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice...
Nov 7, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late stage biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for Q3, the quarter ended September 30, 2013, and provided an update ...
Oct 31, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the comp...
Oct 22, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today plans to reduce operating expenses by eliminating approximately fifty percent of its staff positi...
Oct 16, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Comm...
Oct 16, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that NASDAQ has halted trading of the company's shares. The U.S. Food and Drug Administr...
Oct 9, 2013
Approval of the ANCHOR sNDA Would Expand Use of Vascepa to Include the Treatment of Patients with High Triglycerides (≥200 mg/dL and ...
Oct 3, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it was notified by the U.S. Food and Drug Administration (FDA) that the scheduled advisory co...
Sep 25, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the number of patients enrolled in the company's REDUCE-IT cardiovascular outcomes study o...
Sep 18, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 18, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's President, is scheduled to present a general company update at the 2013 A...
Sep 9, 2013
BEDMINSTER, N.J., and DUBLIN, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it now has 30 patents issued or allowed by the United States Patent and Trademark Office (USPTO) rel...
Aug 26, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the submission of a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administra...
Aug 13, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 13, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's President, is scheduled to present a general company update at the Canacco...
Aug 8, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 8, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for Q2, the quarter ended June 30, 2013, and provided an update on co...
Aug 2, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the compan...
Jul 12, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, July 12, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) ("Amarin" or the "Company") today announced that it had completed its previously announced underwritten public offering of 21,700,000 American Depositary Shares ("ADSs"). The underwriters purchased the ADSs from Amarin at a price of $5.60 pe...
Jul 8, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, July 8, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) ("Amarin" or the "Company") today announced that it is offering to sell 21,700,000 American Depositary Shares ("ADSs") in an underwritten public offering. Amarin has also granted the underwriters a 30-day option to purchase an additional 3,25...
Jun 21, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, June 21, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the results from a Phase 1 clinical trial that compared bioavailability of components from a fi...
Jun 19, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, June 19, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it was informed yesterday by the U.S. Food and Drug Administration (FDA) that the FDA will c...
May 30, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, May 30, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's President, is scheduled to present a general company update at the Jefferie...
May 30, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, May 30, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today presented additional data on Vascepa® (icosapent ethyl) and its effect on lipoprotein particle concentr...
May 22, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, May 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice...
May 9, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, May 9, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended March 31, 2013 and provided an update on compan...
May 3, 2013
BEDMINSTER, N.J. and DUBLIN, May 3, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first ...
Apr 30, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, April 30, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the approval of the Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administr...
Apr 23, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, April 23, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the Food and Drug Administration (FDA) has accepted its Supplemental New Drug Application (...
Apr 18, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, April 18, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the approval of the Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administr...
Apr 8, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, April 8, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today additional data from Amarin's previously announced MARINE and ANCHOR Phase 3 clinical trial resu...
Mar 7, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, March 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notic...
Feb 28, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 28, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter and year ended December 31, 2012 and provided an upd...
Feb 26, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 26, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it has submitted a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Admi...
Feb 22, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the comp...
Feb 21, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 21, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer, is scheduled to present a gener...
Feb 12, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notice o...
Feb 7, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's President, is scheduled to present a general company update at the Leerink...
Feb 7, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notice o...
Feb 1, 2013
Patent Application Related to High (≥200 mg/dL to ...
Jan 31, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notices ...
Jan 24, 2013
-First and Only FDA Approved Pure-EPA Omega-3 Prescription Therapy Now Available- -Vascepa Reduces VHTG Without Raising LDL Cholesterol- ...
Jan 23, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 23, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice...
Jan 22, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that additional data from its pivotal MARINE and ANCHOR Phase 3 clinical trials are now available...
Jan 11, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 11, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notice ...
Jan 2, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer, is scheduled to present a compan...
Jan 2, 2013
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the late December 2012 submission of a Supplemental New Drug Application (sNDA) to the U.S. Food a...
Dec 19, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 19, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the submission of a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administra...
Dec 17, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 17, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it has completed dosing and pharmacokinetic sampling in a study to test a fixed-dose combin...
Dec 13, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 13, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notice ...
Dec 12, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 12, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that David Stack, President and Chief Executive Officer of Pacira Pharmaceuticals, has joined Am...
Dec 11, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 11, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the development of therapeutics to improve cardiovascular health, today announced the addition of an exclusive consortium of companies led by Slanmhor Pharmaceutical, Inc. (Slanmhor) to its planned act...
Dec 6, 2012
Steps Are Consistent With Amarin's Continuation of Its Strategy to Parallel Process Three Strategic Options Conference Call Scheduled for Today, December 6th at 4:30 p.m. ET BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 6, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commerc...
Dec 4, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 4, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering Amarin's Vascepa...
Nov 27, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 27, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering Amarin's Vascepa&#...
Nov 26, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 26, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notice ...
Nov 20, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 20, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering Amarin's Vascepa&#...
Nov 19, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 19, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notice ...
Nov 8, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended September 30, 2012 and provided an update on company opera...
Nov 1, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 1, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it will host a conference call with members of Amarin senior management to discuss the compan...
Oct 30, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 30, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering the pharmaceutical...
Oct 23, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 23, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued two patents covering the use of Amar...
Sep 10, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 10, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Noti...
Sep 6, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 6, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notic...
Sep 5, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 5, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notices...
Sep 4, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 4, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice...
Aug 28, 2012
Reductions in Lipoprotein Particle Concentration Shown in Patients With Severe (≥500 mg/dL) Hypertriglyceridemia BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 28, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiova...
Aug 8, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 8, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended June 30, 2012 and provided an update on company operations...
Jul 31, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, July 31, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it will host a conference call with members of Amarin senior management to discuss the compa...
Jul 26, 2012
Approval Based on Positive Results From MARINE Study Conference Call Scheduled for Today, July 26th at 7:00 p.m. EDT BEDMINSTER, N.J. and DUBLIN, Ireland, July 26, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve car...
Jul 25, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, July 25, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on the development of therapeutics to improve cardiovascular health, announced today that the European Patent Office has issued an intention to grant letter for European Patent Application Numb...
Jul 24, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, July 24, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that the results of its pivotal ANCHOR Phase 3 clinical trial are now available electronically through The American Journal of Cardiology and are sch...
Jul 2, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, July 2, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for U.S. Patent Application Serial Numb...
Jun 4, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, June 4, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that data from the AMR101 pivotal Phase 3 ANCHOR study will be presented in a poster at the American Diabetes Association's (ADA) 72nd Scientific Sess...
May 29, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, May 29, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that John F. Thero, Amarin's President, is scheduled to present a general corporate update at the Jefferies 2012 Global Healthcare Conference to b...
May 29, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, May 29, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering the pharmaceutical composition of Amarin's AMR101 based on U.S. Patent A...
May 24, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, May 24, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that additional data from the AMR101 pivotal Phase 3 studies (MARINE and ANCHOR) will be presented along with an encore presentation of the ANCHOR stud...
May 8, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, May 8, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced financial results for the quarter ended March 31, 2012 and provided an update on company operations. Amarin noted the following highlights sinc...
May 1, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, May 1, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2012 financial results and provide a...
Mar 20, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, March 20, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for U.S. Patent Application Seria...
Mar 6, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, March 6, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Amarin management is scheduled to present a corporate overview and general corporate update at the 24th Annual ROTH OC Growth Stock Conferen...
Feb 29, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 29, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced financial results for the quarter and year ended December 31, 2011 and provided an update on company operations. Key Amarin accomplishments si...
Feb 22, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 22, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that it will host a conference call with members of Amarin senior management to discuss the company's fourth quarter and year-end 2011 financial resul...
Feb 22, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 22, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph S. Zakrzewski, Amarin's Chairman and Chief Executive Officer, is scheduled to present a general corporate update at the CITI 2012 Glo...
Feb 16, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 16, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Steven Ketchum, Ph.D., has been appointed President of Research and Development, Senior Vice President, effective February 16, 2012. Dr. Ke...
Feb 13, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 13, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, announced today that it was informed by the U.S. Food and Drug Administration (FDA) that no advisory committee meeting will be scheduled in connection with the F...
Feb 7, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 7, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease today announced that John F. Thero, Amarin's President, is scheduled to present at the Leerink Swann 2012 Global Healthcare Conference on Thursday, February 16, 20...
Jan 4, 2012
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 4, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) announced today that its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the "Issuer"), priced its previously announced offering of $150 million in aggregate principal amount of e...
Jan 3, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 3, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) announced today that its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the "Issuer"), has commenced an offering of $150 million in aggregate principal amount of exchangeable se...
Jan 3, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 3, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today issued its annual letter to shareholders. The text of this letter, written by Joseph S. Zakrzewski, Chairman and Chief Executive Officer, and the managemen...
Dec 19, 2011
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced the appointment of Joseph T. Kennedy to the newly created position of Senior Vice President, General Counsel. Mr. Kennedy will report to Joseph ...
Dec 14, 2011
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 14, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Patrick "Paddy" O'Sullivan has joined the Board of Directors as an independent director effective December 13, 2011. Mr. O'Sullivan will als...
Dec 7, 2011
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 7, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced the dosing of the first patient in REDUCE-IT, the cardiovascular outcomes study utilizing AMR101. REDUCE-IT (Reduction of Cardiovascular ...
Nov 25, 2011
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 25, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that its New Drug Application (NDA) for AMR101 has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the NDA ...
Nov 25, 2011
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 25, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that Dr. David Feigal has resigned as a member of the Company's Board of Directors. Dr. Feigal cited a crush of other commitments as the reason for h...
Nov 21, 2011
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 21, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that it has been selected for addition to the NASDAQ Biotechnology Index ® (Nasdaq:NBI), which will become effective at the open of U.S. markets...
Nov 16, 2011
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 16, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the first presentation in a scientific session of data from Amarin's Phase 3 clinical trial, the ANCHOR study, in which patients with high trigl...
Nov 15, 2011
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 15, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced the presentation of data from Amarin's Phase 3 clinical trial, the MARINE study, in which patients with very high trigylcerides (≥500 mg/dl...
Nov 14, 2011
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, announced that data from each of its two pivotal Phase 3 studies, the ANCHOR trial and the MARINE trial, will be presented at the American Heart Association's Sc...
Nov 10, 2011
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 10, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease today announced that it is scheduled to participate in two upcoming investor conferences: the Lazard Capital Markets 8th Annual Healthcare Conference on Tuesday, ...
Nov 7, 2011
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 7, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported financial and operating results for the quarter ended September 30, 2011 (Q3 2011). Highlights since the Company's last quarterly report included: ...
Nov 3, 2011
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 3, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, has scheduled a conference call with members of senior management to discuss the Company's financial results and business initiatives for its fiscal third quarter ...
Oct 31, 2011
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 31, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph Zakrzewski, Amarin's Chairman and CEO, has been invited to ring the closing bell at the NASDAQ MarketSite on Wednesday, Nov. 2nd ...
Sep 26, 2011
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 26, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sal...
Sep 19, 2011
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph Zakrzewski, Amarin's Executive Chairman and Chief Executive Officer, is scheduled to present at the UBS Global Life Sciences Con...
Sep 1, 2011
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that results of its pivotal MARINE Phase 3 clinical trial were published in the September issue of The American Journal of Cardiology. The C...
Aug 25, 2011
BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 25, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that data from the pivotal Phase 3 MARINE trial investigating AMR101 as a treatment for very high triglycerides (≥500 mg/dL)will be pr...
Aug 12, 2011
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 12, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph Zakrzewski, Amarin's Executive Chairman and Chief Executive Officer, will present at the Wedbush Securities 2011 Life Sciences Manag...
Aug 10, 2011
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 10, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) agreement for the design o...
Aug 9, 2011
- Company on Track for NDA Filing This Quarter - - Conference Call Set for 8:00 am EDT August 10 - MYSTIC, Conn. and DUBLIN, Aug. 9, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported financial and operating results for the quar...
Aug 8, 2011
MYSTIC, Conn. and DUBLIN, Aug. 8, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that John Thero, Amarin's President, will present at the 2011 Canaccord Genuity Growth Conference to be held at the Intercontinental Hotel in Boston. The ...
Aug 8, 2011
MYSTIC, Conn. and DUBLIN, Aug. 8, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, has scheduled a conference call with members of senior management to discuss the Company's financial results and business initiatives for its fiscal second quarter on Wednesda...
Aug 4, 2011
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 4, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that data from each of its two pivotal Phase 3 studies, the ANCHOR trial and the MARINE trial, will be presented at the American Heart Associatio...
Aug 1, 2011
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the successful completion of all remaining studies required for the Company's planned new drug application (NDA) for AMR101 for the treatment of ...
Jul 7, 2011
MYSTIC, Conn. and DUBLIN, July 7, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the successful completion of the remaining non-clinical studies for the Company's planned new drug application (NDA) for AMR101 for the treatment of patie...
Jun 1, 2011
MYSTIC, Conn. and DUBLIN, Ireland, June 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph Zakrzewski, Amarin's Executive Chairman and Chief Executive Officer, will present at the Jefferies 2011 Global Healthcare Conference ...
May 31, 2011
MYSTIC, Conn. and DUBLIN, May 31, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the expansion of its capability to supply AMR101 through the addition of two active pharmaceutical ingredient (API) suppliers and two encapsulators. ...
May 19, 2011
NEW YORK, May 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today summarized additional MARINE Phase 3 pivotal trial results being presented at the National Lipid Association 2011 Annual Scientific Sessions (NLA) in New York City. In November 201...
May 19, 2011
-EPA Therapy Demonstrates a Wide Range of Lipid Lowering Benefits Without the LDL-C Increase as Seen With Omega-3s Containing DHA- -Amarin's AMR101 Contains >96% EPA- NEW YORK, May 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular diseas...
May 10, 2011
DUBLIN and MYSTIC, Conn., May 10, 2011 /PRNewswire/ -- Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported financial results for the quarter ended March 31, 2011 (Q1 2011). The Company also provided an update on its business progress related to the development program o...
Apr 26, 2011
MYSTIC, Conn. and DUBLIN, April 26, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that John Thero, Amarin's President, will present at the Deutsche Bank 26th Annual Healthcare Conference to be held at the InterContinental Hotel in Boston...
Apr 18, 2011
MYSTIC, Conn. and DUBLIN, April 18, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101. The Phase 3 trial met its prima...
Apr 5, 2011
MYSTIC, Conn. and DUBLIN, April 5, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that data from the MARINE trial, a pivotal Phase 3 study investigating AMR101 as a treatment for very high triglycerides (≥500 mg/dL), will be present...
Mar 31, 2011
MYSTIC, Conn. and DUBLIN, March 31, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Executive Chairman and Chief Executive Officer, Joseph Zakrzewski, will present at 8:40 a.m. EDT on April, 6, 2011 at the 10th Annual Needham Healthca...
Mar 16, 2011
DUBLIN and MYSTIC, Conn., March 16, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported financial results for the fiscal year and fourth quarter ended December 31, 2010. The Company also provided an update on its progress with the Phase 3 developmen...
Mar 8, 2011
MYSTIC, Conn. and DUBLIN, March 8, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to participate in two upcoming investor conferences: the Barclays Capital 2011 Global Healthcare Conference on Tuesday, March 15, 2011 and the ROTH 23rd Annual OC Growth Stock Conference on Wednesday, March 16, 2011. ...
Feb 22, 2011
MYSTIC, Conn. and DUBLIN, Feb 22, 2011 Amarin Corporation plc (Nasdaq: AMRN) today announced that members of its senior management team will be presenting at two investor conferences on March 2, 2011. Joseph Zakrzewski, Executive Chairman and Chief Executive Officer, is scheduled to present at the CITI 2011 Global Healthcare Conference on Wednes...
Feb 7, 2011
MYSTIC, Conn. and DUBLIN, Feb. 7, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference on Wednesday, February 16, 2011. Amarin's participation includes both a panel discussion on Cardiology at 7:45am ET and a company prese...
Feb 2, 2011
DUBLIN and MYSTIC, Conn., Feb. 2, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Paul E. Huff has joined the Company as Chief Commercial Officer. In this role, Mr. Huff is responsible for driving Amarin's AMR101 commercialization str...
Jan 31, 2011
DUBLIN and MYSTIC, Conn., Jan. 31, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today issued a special letter to its shareholders. The text of the letter, written by Joseph S. Zakrzewski, Executive Chairman and Chief Executive Officer of Amarin, follow...
Jan 11, 2011
MYSTIC, Conn. and DUBLIN, Jan. 11, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) (the "Company"), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it has completed its previously announced underwritten public offering of American Depositary Shares ("ADSs") at a price to the public ...
Jan 7, 2011
MYSTIC, Conn. and DUBLIN, Jan. 7, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) (the "Company"), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares ("ADSs"), the underwriters of th...
Jan 6, 2011
MYSTIC, Conn. and DUBLIN, Jan. 6, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) (the "Company"), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced the pricing of an underwritten public offering of 12,000,000 American Depositary Shares ("ADSs") at a price to the public of $7.60 per ADS. T...
Jan 5, 2011
MYSTIC, Conn. and DUBLIN, Jan. 5, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) (the "Company"), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it intends to offer for sale its American Depositary Shares in an underwritten public offering. Jefferies & Company, Inc. and Leerink Sw...
Jan 5, 2011
MYSTIC, Conn. and DUBLIN, Jan. 5, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2011 at 1:00pm PST. The conference will be held at the Westin St. Francis Hotel in San Francisco. A live audio webcast of the pr...
Dec 16, 2010
MYSTIC, Conn., and DUBLIN, Dec. 16, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporti...
Dec 3, 2010
MYSTIC, Conn. and DUBLIN, Dec. 3, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference on Tuesday, December 7, 2010 at 3:00pm PST. The conference will be held at the Nikko Hotel in San Francisco. A liv...
Nov 29, 2010
MYSTIC, Conn. and DUBLIN, Nov. 29, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101. The MAR...
Nov 26, 2010
MYSTIC, Conn. and DUBLIN, Nov. 26, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it will host a conference call at 8:30 a.m. EST on Monday, November 29, 2010, to discuss the top-line results from its Phase 3 MARINE trial. ...
Nov 18, 2010
DUBLIN and MYSTIC, Conn., Nov. 18, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced the appointment of Kristine Peterson to its board of directors. Ms. Peterson has more than 27 years of pharmaceutical industry experience, inc...
Nov 15, 2010
DUBLIN and MYSTIC, Conn., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to present at the Lazard Capital Markets 7th Annual Healthcare Conference on Tuesday, November 16, 2010 at 3:10pm.  Representing Amarin at this conference will be Joseph Zakrzewski, Chairman and Chief Executiv...
Nov 10, 2010
DUBLIN, Ireland and MYSTIC, Conn., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported its financial and operational results for the three-month period ended September 30, 2010.  In addition, the Company provided an update regardi...
Nov 10, 2010
DUBLIN and MYSTIC, Conn., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that, effective November 10, 2010, Joseph S. Zakrzewski has been appointed Chief Executive Officer.  Mr. Zakrzewski has served as the Chairman of ...
Nov 9, 2010
DUBLIN and MYSTIC, Conn., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) has scheduled a conference call for Wednesday, November 10, 2010 at 11:00 am Eastern Time (4:00 pm UTC/GMT) to discuss selected financial and operating results from the third quarter, including a progress update of the Company's MARINE and ANCHOR ...
Oct 28, 2010
DUBLIN and MYSTIC, Conn., Oct 28, 2010 /PRNewswire via COMTEX News Network/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that Dr. Declan Doogan, Chief Medical Officer, is scheduled to present on Amarin's behalf at the Oppenheimer & Co. Inc. 21st Annual Healthcare Conference on Wednesday, November 3, 2010 at 2:10 pm. This conference will...
Oct 18, 2010
DUBLIN and MYSTIC, Conn., Oct 18, 2010 /PRNewswire via COMTEX News Network/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that Dr. Declan Doogan, Chief Medical Officer, is scheduled to present on Amarin's behalf at the NewsMakers in the Biotech Industry Conference on Friday, October 22, 2010 at 2:00 pm. This conference will be held at th...
Sep 16, 2010
DUBLIN and MYSTIC, Conn., Sept 16, 2010 /PRNewswire via COMTEX News Network/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that John Thero, Chief Financial Officer, is scheduled to present on Amarin's behalf at the Global UBS Life Sciences Conference on Wednesday, September 22, 2010 at 12:30 pm. This conference will be held at the Grand ...
Aug 17, 2010
Dublin, Ireland and Mystic, Connecticut, USA, August 17, 2010 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Colin W. Stewart has been appointed President, Chief Executive Officer (CEO) and a member of the Company’s Board ...
Aug 10, 2010
Dublin, Ireland and Mystic, CT, USA, August 10, 2010 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that its MARINE trial, a Phase 3 clinical trial of AMR101, has completed patient enrollment and randomization into the treatment phase of thi...
Aug 10, 2010
Dublin, Ireland and Mystic, CT, USA, August 10, 2010 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reports a financial update as of June 30, 2010. In addition, the Company provides a progress update of its MARINE and ANCHOR trials, the two on-going Phase 3 ...
Aug 3, 2010
Dublin, Ireland and Mystic, CT, USA, August 3, 2010 – Amarin Corporation plc (NASDAQ: AMRN) has scheduled a conference call for Tuesday, August 10, 2010 at 4:00 pm UTC/GMT + 1 hour (11:00 am Eastern Time) to discuss selected financial results and provided a progress update of the Company’s MARINE and ANCHOR, the two Phase 3 cl...
Jul 29, 2010
Dublin, Ireland and Mystic, CT, USA , July 29, 2010 – Amarin Corporation plc (NASDAQ: AMRN) today announced that Dr. Declan Doogan, Interim Chief Executive Officer, is scheduled to present at the 30th Annual Canaccord Genuity Global Growth Conference on Thursday, August 12, 2010 at 1:30pm (EDT). This conference will be held at the I...
Jun 4, 2010
DUBLIN and MYSTIC, Conn., June 4 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq:AMRN - News) today announced that members of its senior management team will be presenting at two upcoming investor conferences. Dr. Declan Doogan, Interim Chief Executive Officer, is scheduled to present at the Jefferies 2010 Global Life Sci...
May 13, 2010
Dublin, Ireland and Mystic, CT, USA, May 13, 2010 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company with a focus o...
May 12, 2010
DUBLIN and MYSTIC, Conn., May 12 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq:AMRN - ...
Apr 27, 2010
Dublin, Ireland and Mystic, CT, USA , April 27, 2010 – Amarin Corporation plc (NASDAQ: AMRN) today announced that John Thero, Chief Financial Officer, is scheduled to present at Deutsche Bank Securities 35th Annual Health Care Conference.  The presentation will be made on Monday, Ma...
Mar 3, 2010
DUBLIN and MYSTIC, Conn., March 3 /PRNe...
Feb 11, 2010
DUBLIN and MYSTIC, Conn., Feb. 11 -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, is pleased to announce the appointment of Mr. Jan...
Feb 2, 2010
DUBLIN and MYSTIC, Conn., Feb. 2 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announce...
Jan 28, 2010
Dublin, Ireland and Mystic, CT, USA, January 28, 2010 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today issued a special letter to its shareholders. The text of the letter, written by Dr. Declan Doogan, Amarin’s Interim...
Jan 11, 2010
San Francisco, CA, USA, January 11, 2010 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today announced that first patients were enrolled i...
Dec 2, 2009
Dublin, Ireland and Mystic, Connecticut, USA, December 2, 2009 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced Joseph S. Zakrzewski will join the Company’s Board of Directors as Executive Chairman effective January 1, 2010....
Nov 23, 2009
DUBLIN, Ireland, November 23, 2009 – Amarin Corporation plc (NASDAQ: AMRN) announced today that it has sent to its shareholders a Notice of the Annual General Meeting of the Company, which will be held on December 21, 2009 in Dublin, Ireland.    Copies of the Notice, togethe...
Nov 13, 2009
Ft. Lee, N.J. (November 11, 2009) – Amarin Corp.(NASDAQ: AMRN), a clinical stage pharmaceutical company with R&D operations based in Mystic, Conn., has joined SAFE-BioPharma Association, the non-profit association ...
Nov 6, 2009
DUBLIN, Ireland, November 6th, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced the appointment of John F. Thero as the Company’s Chief Financial Officer. In this role, Mr. Thero will have broad responsibility for financial and administrative matters of the Company and be actively involved in corporate devel...
Oct 19, 2009
DUBLIN, Ireland, October 19, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced it has closed its $70 million private placement. The transaction was led by existing investor, Fountain Healthcare Partners, on behalf of funds affiliated with other existing investors Sofinnova Ventures, Orbimed Advisors and Longitude C...
Oct 19, 2009
DUBLIN, Ireland, October 19, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has executed an agreement with Medpace, Inc. (‘Medpace’), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services i...
Oct 13, 2009
DUBLIN, Ireland, October 13, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced it has entered into a definitive agreement with several existing and new institutional and accredited investors for a $70 million private placement. The private placement of units for $70 million consists of $66.4 million in cas...
Oct 13, 2009
DUBLIN, Ireland, October 13, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced changes to its board and management team, in conjunction with its separately announced $70 million private placement. Following the closing of the financing, Mr. Thomas Lynch, Chairman and Chief Executive O...
Oct 5, 2009
DUBLIN, Ireland, October 5, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that Nasdaq has granted the Company’s requested extension to the deadline to file its 2008 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission to regain compliance with Nasdaq's filing ...
Oct 1, 2009
DUBLIN, Ireland, October 1, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has reached an agreement with the lenders of the Company’s $5.5 million bridge financing to extend the maturity date to October 16, 2009. This extension provides the Company with additional time to con...
Aug 3, 2009
DUBLIN, Ireland, August 3, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has executed an agreement for the private placement of convertible bridge loan notes (“Bridge Financing”) in the amount of $3.0 million with select accredited and institutional investors, including funds managed by Mids...
Jul 9, 2009
DUBLIN, Ireland, July 9, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for its planned Phase 3 clinical trial of AMR101 (ethyl-EPA) in patients with mixed dyslipidemia. Renowned cardiologist ...
Jul 7, 2009
DUBLIN, Ireland, July 7, 2009 – Amarin Corporation plc (NASDAQ: AMRN) announced today that that it has entered into a non-binding term sheet with certain existing investors relating to the proposed private placement of American Depositary Shares (each representing one ordinary share) (“ADSs”) for up to $55 million...
Jul 7, 2009
DUBLIN, Ireland, July 7, 2009 – Amarin Corporation plc (NASDAQ: AMRN) announced today that on July 6, 2009, the Company received a written notification from the Nasdaq Stock Market stating that it is not in compliance with the filing requirements for continued listing under Nasdaq Marketplace Rule 5250...
Jul 1, 2009
DUBLIN, Ireland, July 1, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today reported preliminary unaudited financial results for the six and twelve months ended December 31, 2008. For the six months ended December 31, 2008, Amarin reported a net loss of $13.3 million or $0.49 per share, compared with a net loss of $13.4 milli...
Jul 1, 2009
DUBLIN, Ireland, July 1, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today reported preliminary unaudited financial results for the six and twelve months ended December 31, 2008. For the six months ended December 31, 2008, Amarin reported a net loss of $13.3 million or $0.49 per share, compared with a net loss of $13.4 milli...
Jun 22, 2009
DUBLIN, Ireland, July 22, 2009 – Amarin Corporation plc (NASDAQ: AMRN) announced today that it has revised the terms of the previously announced non-binding term sheet relating to the private placement of American Depositary Shares (each representing one ordinary share) (“ADSs”) for up to $55 million. The ...
Jun 10, 2009
DUBLIN, Ireland, June 10, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced encouraging top line results from an exploratory Phase 2a multi-centre, dose-ranging, cross-over clinical study of EN101 in patients with myasthenia gravis, a chronic autoimmune disease characterized by muscle weakness which can be life-thr...
May 26, 2009
DUBLIN, Ireland, May 26, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has signed a term sheet for a private placement of convertible bridge loan notes (“Bridge Financing”) in the amount of $2.6 million with certain existing investors in the Company, including a number of current directors o...
May 6, 2009
DUBLIN, Ireland, May 6, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for its planned Phase 3 registration clinical trial of AMR101 (ethyl-EPA) in patients with hypertriglyceridemia, or very ...
Apr 8, 2009
DUBLIN, Ireland, April 8, 2009 – Amarin Corporation plc (NASDAQ: AMRN) todayannounced that the European Medicines Agency (EMEA) has accepted for review theCompany's Marketing Authorization Application (MAA) for AMR101 (ultra-pure ethyl-EPA) in patients with Huntington’s disease....
Mar 11, 2009
DUBLIN, Ireland, March 11, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that Mr. Thomas Lynch, Chairman and Chief Executive Officer, will present at the Cowen and Company 29th Annual Health Care Conference on Wednesday, March 18, 2009 at 8.00 am Eastern Time. The event will be held from March 16-19, 2009 at th...
Feb 3, 2009
DUBLIN, Ireland, February 3, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that Mr. Thomas Lynch, Chairman and Chief Executive Officer, will present at the upcoming 11th Annual BIO CEO & Investor Conference on Monday, February 9, 2009 at 2.45 pm Eastern Time. The event will be held on Februa...
Page:
...
Next Last
 
= add release to Briefcase